KAWACALP study: the utility of serum calprotectin as a prognostic biomarker in Kawasaki disease.
Mercader Rodríguez Beatriz B, Avilés Plaza Francisco V FV, Sorlí García Moisés M, Fernández Cooke Elisa E et al.
To assess if serum calprotectin (sCP) can be used as a predictor of resistance to intravenous immunoglobulin treatment (IVIG) and coronary artery aneurysms (CAA) in Kawasaki disease (KD). A multicenter, observational, cohort study was conducted prospectively between September 2018 and February 2023. sCP was analyzed at four points in the evolution of KD in 74 patients from four Spanish hospitals. The sCP and other clinical and analytical values were compared between groups: IVIG responders or sensitive KD patients (SKD) versus IVIG nonresponders or refractory KD patients (RKD), and KD patients with CAA versus those without CAA. In refractory KD patients and in those who developed CAA, sCP was higher at the moment of diagnosis and remained elevated after treatment with IVIG, unlike what happened in sensitive KD patients and in those without CAA. A post-treatment sCP level ≥ 14.09 μg/ml predicted RKD with Sn 75% and Sp 72.97% (AUC 0.75). A pre-treatment sCP cutoff of ≥ 21.49 μg/ml predicted CAA with Sn:100% and Sp 71.05% (AUC 0.86). A post-treatment sCP value ≥ 14.76 μg/ml predicted CAA with S 71.43% and Sp 76.32% (AUC 0.74). Serum CP at the time of diagnosis ≥ 21.49 μg/ml has a sensitivity of 100% to detect CAA. Therefore, if these results are confirmed in larger studies, sCP may be used as a prognostic biomarker in patients with Kawasaki disease, to detect early patients with a higher probability of CAA occurrence, guide treatment decisions and ultimately reduce cardiac complications. • At present, no validated biomarkers allow early identification of IVIG resistance or predict coronary involvement in KD patients. • High serum calprotectin level at the diagnosis of KD and persistently elevated levels after IVIG treatment may identify patients at risk for IVIG resistance and coronary complications.